DE69928244D1 - Inhibitoren der nf-kb aktivierung - Google Patents

Inhibitoren der nf-kb aktivierung

Info

Publication number
DE69928244D1
DE69928244D1 DE69928244T DE69928244T DE69928244D1 DE 69928244 D1 DE69928244 D1 DE 69928244D1 DE 69928244 T DE69928244 T DE 69928244T DE 69928244 T DE69928244 T DE 69928244T DE 69928244 D1 DE69928244 D1 DE 69928244D1
Authority
DE
Germany
Prior art keywords
inhibitors
kappab
activation
ikappab
traf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928244T
Other languages
English (en)
Other versions
DE69928244T2 (de
Inventor
Rudi Beyaert
Karen Heyninck
Walter Fiers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of DE69928244D1 publication Critical patent/DE69928244D1/de
Application granted granted Critical
Publication of DE69928244T2 publication Critical patent/DE69928244T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69928244T 1998-05-06 1999-05-05 Inhibitoren der nf-kb aktivierung Expired - Lifetime DE69928244T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98201472 1998-05-06
EP98201472 1998-05-06
PCT/BE1999/000055 WO1999057133A2 (en) 1998-05-06 1999-05-05 Inhibitors of nf-kb activation

Publications (2)

Publication Number Publication Date
DE69928244D1 true DE69928244D1 (de) 2005-12-15
DE69928244T2 DE69928244T2 (de) 2006-08-10

Family

ID=8233686

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928244T Expired - Lifetime DE69928244T2 (de) 1998-05-06 1999-05-05 Inhibitoren der nf-kb aktivierung

Country Status (9)

Country Link
US (2) US6673897B1 (de)
EP (1) EP1075519B1 (de)
JP (1) JP2002513552A (de)
AT (1) ATE309352T1 (de)
AU (1) AU754434B2 (de)
CA (1) CA2328483A1 (de)
DE (1) DE69928244T2 (de)
ES (1) ES2251831T3 (de)
WO (1) WO1999057133A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2251831T3 (es) 1998-05-06 2006-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Inhibidores de la activacion de nf-kb.
GB9930616D0 (en) * 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
WO2003000280A2 (en) * 2001-06-22 2003-01-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Abin-mediated hepatitis protection
BRPI0414714A (pt) 2003-09-24 2006-11-21 Pasteur Institut polinucleotìdeo purificado, vetor, célula hospedeira, construto de fusão de polipeptìdeo, métodos de inibir a rota de sinalização de nf-capab, de interromper a oligomerização de nemo, e, de identificar polipeptìdeos que modulam a oligomerização de nemo, e, uso de uma quantidade eficaz de uma composição
WO2006029981A1 (en) * 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
CN1304418C (zh) * 2005-02-22 2007-03-14 中国人民解放军第三军医大学第三附属医院 核因子－κB p65亚基拮抗肽及其应用
WO2006108844A1 (en) * 2005-04-14 2006-10-19 Vib Vzw Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab)
ES2729501T3 (es) * 2006-10-30 2019-11-04 Centre Nat Rech Scient Ensayo de gen indicador, kit y células con sensibilidad y/o especificidad mejoradas para determinar el nivel del TNF-gamma
CN101307094B (zh) * 2008-03-21 2011-09-28 中国人民解放军第三军医大学第三附属医院 一种核因子-κB p65亚基拮抗多肽
CN101798336B (zh) * 2009-02-06 2012-02-29 中国人民解放军第三军医大学第三附属医院 一种具有示踪功能的抗肿瘤化合物
CN111606976A (zh) * 2020-05-26 2020-09-01 中国人民解放军军事科学院军事医学研究院 一种小肽及其在抑制阿片成瘾性和耐受性上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
UA71889C2 (uk) * 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
ES2251831T3 (es) 1998-05-06 2006-05-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Inhibidores de la activacion de nf-kb.

Also Published As

Publication number Publication date
WO1999057133A2 (en) 1999-11-11
JP2002513552A (ja) 2002-05-14
CA2328483A1 (en) 1999-11-11
WO1999057133A3 (en) 2000-02-24
US7414026B2 (en) 2008-08-19
EP1075519A2 (de) 2001-02-14
US6673897B1 (en) 2004-01-06
AU4124499A (en) 1999-11-23
EP1075519B1 (de) 2005-11-09
ES2251831T3 (es) 2006-05-01
DE69928244T2 (de) 2006-08-10
AU754434B2 (en) 2002-11-14
US20040092430A1 (en) 2004-05-13
ATE309352T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ATE300597T1 (de) Behandlung von geweben
NO20003096L (no) Sammensetninger og fremgangsmÕter for behandling av ADD
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DK0971713T3 (da) Anvendelse af cholinesteraseinhibitorer til behandling af opmærksomhedsforstyrrelser
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
ES2191830T3 (es) Inhibidores de trombina.
ATE309352T1 (de) Inhibitoren der nf-kb aktivierung
NO965563D0 (no) Behandling og profylakse av osteoporese
DE69836209D1 (de) Vorbeugung und behandlunhg des hepatozellulären krebses
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BR9612283A (pt) Composição para o tratamento de manchas em peças de roupa e métodos de tratamento
EP0992243A4 (de) Stoff für die prophylaxe oder therapie
NO980296L (no) Forbedrede terapeutiske midler
ES2186807T3 (es) Inhibidores de trombina.
NO994631D0 (no) Fremgangsmaater og sammensetninger for behandling av eggstokkreft
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
TR200002939T2 (tr) Paroksetin maleat
NO20010390L (no) Behandling av angstsykdommer
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
NO961113D0 (no) Behandling og forebyggelse av prostatakreft
DE69737570D1 (de) Agentien zur präsymptomatischen Detektion, Prävention und Behandlung von Brustkrebs in Menschen
BR9909868A (pt) Ascorbato de paroxetina

Legal Events

Date Code Title Description
8364 No opposition during term of opposition